Combinations of interleukin-2 with other treatment modalities

Bibliography

• PAUL WE, SEDER RA: Lymphocyte responses and cytokines. Cell (1994) 76(2):241–245.
   PubMed Web of Science ®Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO R: Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science (1976) 193:1007-1008.First paper describing purified T-cell growth factor, now know as IL–2.
   Google Scholar
• SMITH KA: Interleukin-2: inception, impact, and implications. Science (1978) 240:1169–1176.
   Google Scholar
• MUEGGE K, DURUM SK: Cytokines and transcription factors. Cytokine (1991) 2(1):1–8.
   Google Scholar
• BALKWILL FR, BURKE F: The cytokine network. Immunol. Today (1989) 10(9):299–304.
   PubMedGoogle Scholar
• KOLITZ JE, WELTE K, SYKORA K-W, MERTELSMANN R: Interleukin-2: a review. Drug Res. (1985) 35(11) 10:1607–1615.
   Google Scholar
• WHITTINGTON R, FAULDS D: Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs (1993) 46(3):446–514. Nice review of the oneologie clinical applications of IL–2.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: The clinical experience with inter leukin-2 in cancer therapy. Cancer Biotherapy (1994) 9(3):183–209.
   PubMedGoogle Scholar
• Very thoughtful review by an investigator with significant IL-2 clinical experience.
   Google Scholar
• DINARELLO CA, MIER JVV: Interleukins. Ann. Rev. Med. (1986) 37:173–178.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Hellman S, Rosenberg SA (Eds.), JB Lippincott Company, Philadelphia(1995) 9:207–233.
   Google Scholar
• Excellent review of the science of biologicals, IL-2 in particular.
   Google Scholar
• DeVita VT, Hellman S, Rosenberg SA (Eds.), JB Lippincott Company, Philadelphia (1995) 10:235–249.
   Google Scholar
• Very good review of toxicity and management of IL-2.
   Google Scholar
• SMITH KA: Lowest dose interleukin-2 immunotherapy. Blood (1993) 81(6):1414–1423.
   PubMed Web of Science ®Google Scholar
• Nice review from one of the proponents of very low dose IL-2.
   Google Scholar
• LINDEMANN A, BROSSART P, HOFFKEN K, et al.: Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a Phase IB study. Cancer Immunol. Immunother. (1993) 37:307–315.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HANK JA, KHORSAND M, et al.: Clinical and immunological effects of granulo- cyte-macrophage colony-stimulating factor co-administered with interleukin-2: a Phase IB study. Clin. Cancer Res. (1996) 2:319–330.
   PubMed Web of Science ®Google Scholar
• Useful description of combination cytokine clinical therapy.
   Google Scholar
• MASUMORI N, TSUKAMOTO T, KUMAMOTO Y: Interferon-gamma and interleukin-2 sup-press the experimental metastasis of mouse renal adenocarcinoma. Int. J. Urol. (1995) 2:6–11.
   PubMedGoogle Scholar
• IIGO M, TSUDA H, MORIYAMA M: Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2. Clin. Exp. Metastasis (1994) 12(6):368–374. Good studies evaluating combination chemotherapy and cytokine therapy.
   PubMed Web of Science ®Google Scholar
• PARKINSON DR: Biological response modifiers: II. Cancer. Present status of biological response modifiers in cancer. Am. J. Med. (1995) 99(Suppl. 6A):6A-54S-6A56S. Good review by investigator with broad biologics expertise.
   PubMedGoogle Scholar
• GANSBACHER B, ZIER K, DANIELS B, et al.: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. (1990) 172:1217–1224.
   PubMed Web of Science ®Google Scholar
• FOA R, GUARINI A, GANSBACHER B: IL-2 treatment for cancer: from biology to gene therapy. Br. J. Cancer (1992) 66:992–998.
   PubMed Web of Science ®Google Scholar
• ROYAL RE, STEINBERG SM, KROUSE RS, et al.: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer I Sci. Am. (1996) 2(2):91–98.
   PubMedGoogle Scholar
• SZNOL M, PARKINSON DR: Clinical applications of IL-2. Oncology (1994) 8(6):61–67.
   PubMedGoogle Scholar
• DeVita VT, Hellman S, Rosenberg SA (Eds.), JBLippincott Company, Philadelphia (1993) 9:150–181.
   Google Scholar
• Probably the premier Cancer Textbook; excellent reference.
   Google Scholar
• PETERSEN EA, RIFKIND D: Infectious disease: new organisms, new diseases and expanding new antimicrobial agents. Ariz. Med. (1984) 41(6):385–389.
   PubMedGoogle Scholar
• CHANG W-C, HSIAO MH, PATTENGALE PK: Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. Nat. Imm. Cell Growth Reg. (1991) 10:57–70.
   PubMedGoogle Scholar
• CHARAK BS, AGAH R, GRAY D, MAZUMDER A: Interaction of various cytokines with interleukin-2 in the generation of killer cells from human bone marrow: application in purging of leukemia. Leukemia Res. (1991) 15(9):801–810.
   PubMed Web of Science ®Google Scholar
• SIEGEL JP, ROOK AH, DJEUJY, QUINNAN GV, Jr.: Interleukin-2 therapy in infectious diseases: rationale and prospects. Infection (1985) 13\(Suppl. 2):5219–5223.
   Google Scholar
• KAPLAN G, BRITTON WJ, HANCOCK GE, et al.: The systemic influence of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J. Exp. Med. (1991) 173:993–1006.
   PubMed Web of Science ®Google Scholar
• SCHAUF V, ROM WN, SMITH KA, et al.: Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J. Infect. Dis. (1993) 168:1056-1059. Good article by pioneers in the field of biologicals and TB.
   PubMedGoogle Scholar
• BERNSTEIN DI, HARRISON CJ, JENSKI LJ, MYERS MG, STANBERRY LR: Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig: effects of glycoprotein immunotherapy. I Immunol. (1991) 146(10):3571–3577.
   Web of Science ®Google Scholar
• ALBANO EA, PIZZO PA: The evolving population of immunocompromised children. Fed. Infect. Dis. 1 (1988) 7(5 Suppl.):79–86.
   Google Scholar
• CASTIGLI E, GEHA RS, CHATILA T: Severe combined immunodeficiency with selective T-cell cytokine genes. Pediatric Res. (1993) 33(Suppl.):S20–S23.
   Google Scholar
• PAHWAR, CHATILA T, PAHWA S, et al.: Recombinant interleukin-2 therapy in severe combined immunodeficiency disease. Proc. Natl. Acad. Sci. USA (1989) 86:5069–5073.
   PubMed Web of Science ®Google Scholar
• RUMP JA, JAHREIS A, SCHLESIER M, et al.: Effects of interleukin-2 therapy in patients with common variable immunodeficiency (CVD)). Immunodeficiency (1993) 4:37–42.
   PubMedGoogle Scholar
• OHNO T, FUJII H, KANOH T, et al.: Selective deficiency in IL-2 production and refractoriness to extrinsic IL-2 in immunodeficiency with hyper-Ig1VI. Clin. ImmunoL ImmunopathoL (1987) 45:471–480.
   PubMedGoogle Scholar
• MERTELSMANN R, WELTE K, STERNBERG C, et al.: Treatment of immunodeficiency with interleukin-2: initial exploration. I Biological Response Modifiers (1984) 4:483–490.
   Google Scholar
• FAUCI AS, ROSENBERG SA, SHERWIN SA, et al.: Immunomodulators in clinical medicine. Ann. Intern. Med. (1987) 106:421–433.
   PubMed Web of Science ®Google Scholar
• Spriggs DR, Koff WC (Eds.), CRC Press, Boca Raton (1991) 4:40–50.
   Google Scholar
• DAVEY RT, Jr., CHAITT DG, PISCITELLI SC, et al.: Subcutaneous administration of interleukin-2 in HIV-1-infected individuals. I Infect. Dis. In press.
   PubMedGoogle Scholar
• KOVACS JA, VOGEL S, ALBERT JM, et al.: Sustained increases in CD4 counts with intermittent interleukin-2 therapy in HIV-infected patients. New Engl. I Med. (1996) 335:1350–1356.
   PubMed Web of Science ®Google Scholar
• Important paper on the current use of IL-2 in HIV positive patients.
   Google Scholar
• FAHEY JL, SARNA G, GALE RP, SEEGER R: Immune interventions in disease. Ann. Intern. Med. (1987) 106:257–274.
   PubMed Web of Science ®Google Scholar
• MANDELBOIM 0, VADAI E, FRIDKIN M, et al.: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Medicine (1995) 1:1179–1183.
   PubMed Web of Science ®Google Scholar
• KUMAR V, SERCARZ E: Genetic vaccination: the advantages of going naked. Nature Medicine (1996) 2:857–858.
   PubMed Web of Science ®Google Scholar
• Editorial on this very interesting new approach to vaccinations.
   Google Scholar
• TASCON RE, COLSTON MJ, RAGNO S, et al.: Vaccination against tuberculosis by DNA injection. Nature Medicine (1996) 2:888–892.
   PubMed Web of Science ®Google Scholar
• MOSSINGHOFF GJ: Over 200 medicines in testing for cancer - the number two killer of Americans. New Medicines in Development for Cancer. PhRMA (May 1995):1.
   Google Scholar
• MOSSINGHOFF GJ: 79 medicines, vaccines in testing for infectious diseases. New Medicines in Development for Infectious Diseases. PhRMA (1994):1.
   Google Scholar
• WANG L, GOILLOT E, TEPPER RI: IL-10 inhibits alloreactive cytotoxic T-lymphocyte generation in vivo. Cellular ImmunoL (1994) 159:152-169.Critical evidence for the immunosuppressive role of IL–10.
   Google Scholar
• BOST KL, BIELIGK SC, JAFFE BM: Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J. ImmunoL (1995) 154:718–729.
   PubMed Web of Science ®Google Scholar
• Important contribution from clinical literature on IL-10 immunosuppressive activities.
   Google Scholar
• BELLONE G, ASTE-AMEZAGA M, TRINCHIERI G, RODECK U: Regulation of NK cell functions by TGF-131.i Immunol. (1995) 155:1066-1073.Significant immunosuppressive role of TGF-I3 described.
   Google Scholar
• SONOUCHI K, HAMILTON TA, TANNENBAUM CS, et al.: Chemokine gene expression in the murine renal cell carcinoma, renca, following treatment in vivo with interferon-a and interleukin-2. Am. I Pathol. (1994) 144(4):747–755.
   PubMed Web of Science ®Google Scholar
• GOEDEGEBUURE PS, ZUBER M, LEONARD-VIDAL et al.: Reactivation of murine tumour-in- filtrating lymphocytes with solid-phase anti-cd3 antibody: in vitro cytokine production is associ-ated with in vivo efficacy. Surg. Oncol. (1994) 3:79–89.
   PubMed Web of Science ®Google Scholar
• Evidence for immunoreactivity of T-cells and in vivo suppression.
   Google Scholar
• HOCK H, DORSCH M, KUNZENDORF U, et al.: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor,or interferon-y. Proc. Natl. Acad. Sci. USA (1993) 90:2774–2778.
   PubMed Web of Science ®Google Scholar
• Mechanisms of tumour escape and rejection studied.
   Google Scholar
• KIM J, MODLIN RL, MOY RL, et al.: IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T-cell immune response. I Immunol. (1995)155:2240–2247.
   Web of Science ®Google Scholar
• Established clear relationship between IL-10 and tumour escape from host recognition.
   Google Scholar
• DUMMER W, BECKER JC, SCHWAAF A, et al.: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. (1995) 5:67-68.Tumour stage found to be associated with circulating levels of IL–10.
   Google Scholar
• SATO T, MCCUE P, MASUOKA K, et al.: Interleukin-10 production by human melanoma. Clin. Cancer Res. (1996) 2:1383-1390. Confirmation and extension of earlier work.
   PubMedGoogle Scholar
• HURFORD RK, DRANOFF G, MULLIGAN RC, TEPPER RI: Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nature Genetics (1995) 10(4):430–435. Excellent examples of the application of gene therapy to tumour models.
   Google Scholar
• KARP SE, FARBER A, SALO JC, et al.: Cytokine secretion by genetically modified non-immunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. (1993) 150(3):896–908.
   PubMed Web of Science ®Google Scholar
• Immunological mechanisms explored that are associated with tumour regression.
   Google Scholar
• GLICK RP, LICHTOR T, KIM TS, ILANGOVAN S, COHEN EP: Fibroblasts genetically engi-neered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery (1995) 36(3):548–555.
   PubMed Web of Science ®Google Scholar
• MUSIANI P, MODESTI A, BRUNETTI M, et al.: Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or inter-feron-y genes. Nat. Immunol. (1994) 13:93–101.
   Google Scholar
• GANSBACHER B: Cytokine gene therapy. Mt. Sinai J. Med. (1994) 61(4):301–309. Good review on gene therapy with cytokines.
   Google Scholar
• CHAPMAN PB, HOUGHTON AN: Non-antibody immunotherapy of cancer. Curr. Opin. Immunol. (1993) 5:726–731.
   PubMed Web of Science ®Google Scholar
• Very good review article focused on cytokines and related therapies.
   Google Scholar
• PARDOLL DM: Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol. (1995) 13:399–415.
   PubMed Web of Science ®Google Scholar
• Excellent review article on the role of cytokines as immunomodulating agents in association with tumour vaccines.
   Google Scholar
• PROIETTI E, TRITARELLI E, GABRIELE L, et al.: Combined interleukin-113/interleukin-2 treat-ment in mice: synergistic myelostimulatory activity and protection against cydophosphamide-induced myelosuppression. Cancer Res. (1993) 53:569–579.
   PubMed Web of Science ®Google Scholar
• FUTAMI H, EADER LA, BACK TT, et al.: Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J. Immunol. (1992) 12(4):247–255.
   Google Scholar
• GARACI E, PICA F, MASTINO A, et al.: Antitumor effect of thymosin oc, 13 following cydophos-phamide in mice injected with highly metastatic friend erythroleukemia cells. J. Immunother. (1993) 13(1):7–17.
   PubMed Web of Science ®Google Scholar
• MAASS G, SCHWEIGHOFFER T, BERGER M, et al.: Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo. Int. J. Immunopharmacol. (1995) 17(2):65–73.
   PubMed Web of Science ®Google Scholar
• MAASS G, SCHMIDT W, BERGER M, et al.: Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin-2-secreting tumor cells: three consecutivestages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA (1995) 92:5540–5544.
   PubMed Web of Science ®Google Scholar
• Significant contribution regarding the application of IL-2 as a vaccine adjuvant for tumours.
   Google Scholar
• BRONTE V, TSUNG K, RAO JB, et al.: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. I Immunol. (1995) 154:5282-5292. Good examples of using IL-2 together with tumour vaccines based on genetic therapy.
   Google Scholar
• SAITO S, BANNERJI R, BANSBACHER B, et al.: Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. (1994) 54:3516–3520.
   PubMed Web of Science ®Google Scholar
• Examples of the application of gene therapy and cancer vaccines.
   Google Scholar
• NANDA NK, SERCARZ EE: Induction of anti-self-immunity to cure cancer. Cell (1995) 82: 13–17.
   Google Scholar
• Novel approach applying immunology and tumour vaccine concepts.
   Google Scholar
• KANG X, KAWAKAMI Y, EL-GAMIL M, et al.: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. (1995) 155:1343-1348. Excellent example of an early identification of a tumour-selective epitope.
   Google Scholar
• COULIE PG, LEHMANN F, LETHE B, et al.: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T-lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA(1995) 92:7976–7980.
   PubMed Web of Science ®Google Scholar
• One of the earliest examples of a melanoma-specific antigen from one of the leading groups in the world on the identification of tumour epitopes.
   Google Scholar
• LINEHAN DC, GOEDEGEBURRE PS, PEOPLES GE, ROGERS SO, EBERLEIN TJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. (1995) 155:4486–4491.
   PubMed Web of Science ®Google Scholar
• Evidence that lymphocytes from tumours can be cytotoxic in the appropriate environment.
   Google Scholar
• MAEURER MJ, MARTIN D, ELDER E, STORKUS WJ, LOTZE MT: Detection of naturally processed and HLA-Al-presented melanoma T-cell epitopes defined by CDS+ T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin. Cancer Res. (1996) 2:87–95.
   PubMed Web of Science ®Google Scholar
• Examples of tumour-selective epitopes as candidates for tumour vaccines.
   Google Scholar
• VAN DEN EYNDE L, BRICHARD VG: New tumor antigens recognized by T-cells. Curr. Opin. Immunol. (1995) 7:674–681.
   PubMed Web of Science ®Google Scholar
• Good review of the subject when it was just emerging as a topic of considerable interest.
   Google Scholar
• DENG W, THIEL B, TANNENBAUM CS, HAMILTON TA, STUEHR DJ: Synergistic co-operation between T-cell lymphokines for induction of the nitric oxide synthase gene in murine peritoneal macrophages. J. Immunol. (1993) 151(1):322–329.
   PubMed Web of Science ®Google Scholar
• VALLERA DA, TAYLOR PA, AUKERMAN SL, BLAZAR BR: Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous co-administration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. (1993) 53:4273–4280.
   PubMed Web of Science ®Google Scholar
• MCADAM AJ, PULASKI BA, HARKINS SS, et al.: Synergistic effects of co-expression of the Thl cytokines IL-2 and IFN-y on generation of murine tumor-reactive cytotoxic cells. Int. J. Cancer (1995) 61:628–63
   PubMed Web of Science ®Google Scholar
• HOCK H, DORSCH M, KUNZENDORF U, et al.: Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. (1993) 53:714–716.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL FM, CRONIN K, BANNERJI R, GOLDE DW, BANSBACHER B: Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-y cDNAs. Blood (1994) 83(5):1289–1298.
   PubMed Web of Science ®Google Scholar
• Significant contribution evaluating cytokine anti-tumour activities conferred through genetic therapy.
   Google Scholar
• SELIGER B, HOHNE A, KNUTH A, et al.: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. (1996) 56:1756–1760.
   PubMed Web of Science ®Google Scholar
• Evidence for altered antigen presentation in tumours, related to escape from host immune response.
   Google Scholar
• MAEURER MJ, GOLLIN SM, STORKUS WJ, et al.: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 61. Clin. Cancer Res. (1996) 2:641–652.
   PubMed Web of Science ®Google Scholar
• ZEA AH, CURTI BD, LONGO DL, et al.: Alterations in T-cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. (1995) 1:1327-1335. Evidence of additional mechanisms of tumour escape from host recognition through alterations in immune cell signalling.
   PubMedGoogle Scholar
• ALLISON JP, HURWITZ AA, LEACH DR: Manipulation of co-stimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. (1995) 7:682–686.
   PubMed Web of Science ®Google Scholar
• Good summary of some of the immune mechanisms associated with tumour escape from the host.
   Google Scholar
• MUKHERJI B, CHAKRABORTY NG, YAMASAKI S, et al.: Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA (1995) 92:8078–8082.
   PubMed Web of Science ®Google Scholar
• Clinical example of utility of melanoma epitopes used for cancer vaccines.
   Google Scholar
• RAMSAY AJ, RUBY J, RAMSHAW IA: A case for cytokines as effector molecules in the resolution of virus infection. Immunol. Today (1993) 14(4):155–157.
   PubMedGoogle Scholar
• Easy to read overview.
   Google Scholar
• TAYLOR C: Cytokines as adjuvants for vaccines: antigen-specific responses differ from poly-clonal responses. Infect. Immun. (1995) 63(9):3241–3244.
   PubMed Web of Science ®Google Scholar
• GUIDOTTI LG, GUILHOT S, CHISARI FV: Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -inde-pendent pathways. J. ViroL (1994) 68(3):1265–1270.
   PubMed Web of Science ®Google Scholar
• Example of anti-HBV cytokine effects.
   Google Scholar
• SCHIJNS VECJ, CLAASSEN IJTM, VERMEULEN AA, HORZINEK MC, OSTERHAUS ADME: Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosisfactor-a, interleukin-la, interleukin-2 and interferon-y on the immunogenicity of an inactivated rabies vaccine. J. Gen. ViroL (1994) 75:55–63.
   PubMed Web of Science ®Google Scholar
• In-depth immunological study of cytokines as adjuvants.
   Google Scholar
• DALEY M, WILLIAMS T, COYLE P, et al.: Prevention and treatment of Staphylococcus aureus infections with recombinant cytokines. Cytokine (1993) 5(3):276–284. Direct therapeutic application of cytokines in infectious disease model.
   Google Scholar
• DALEY MJ, FURDA G, DOUGHERTY R, et al.: Potentiation of antibiotic therapy for bovine mastitis by recombinant bovine interleukin-2. J. Dairy Sci. (1992) 75(12):3330–3338.
   PubMed Web of Science ®Google Scholar
• Example of practical therapeutic application of IL-2.
   Google Scholar
• REDDY DN, REDDY PG, XUE W, et al.: Immunopotentiation of bovine respiratory disease virus vaccines by interleukin-113 and interleukin-2. Vet. ImmunoL ImmunopathoL (1993) 37:25–38.
   PubMed Web of Science ®Google Scholar
• WEINBERG A, MERIGAN TC: Recombinant interleukin-2 as an adjuvant for vaccine-induced protection. J. Immunol. (1988) 140:294-299. One of the earliest examples of the utility of IL-2 as a vaccine adjuvant.
   Google Scholar
• GIEDLIN MA, ZIMMERMAN RJ: The use of recombinant human interleukin-2 in treating infectious diseases. Curr. Opin. BiotechnoL (1993) 4:722–726.
   PubMedGoogle Scholar
• A complete review of the use of IL-2 in infectious diseases.
   Google Scholar
• HUGHES HPA, BABIUK LA: The adjuvant potential of cytokines. Biotechnol. Ther. (1992) 3(3,4):101–117.
   Google Scholar
• Excellent summary article on the possible roles of cytokines as adjuvants.
   Google Scholar
• MOSSINGHOFF GJ: 284 biotechnology products in testing. Biotechnology Medicines in Develop-ment. PhRMA (June 1996):1.
   Google Scholar
• CLINTON B, GORE A: Reinventing the regulation of cancer drugs. National Performance Re-view.US Government Printing Office (1996).
   Google Scholar